http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008094875-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5dd388a5130b0bdede0fdfc6c2af6ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac2bcff3f62de8e5e927104154bc5ef1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B44D3-162 |
| filingDate | 2008-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11f53ee6f6ad00751e17e913fffc7c05 |
| publicationDate | 2008-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008094875-A2 |
| titleOfInvention | Methods for treating bone loss and bone disease associated with chronic kidney disease |
| abstract | Disclosed are methods and preparations for the treatment and or inhibition of bone loss in uremic animals. Leptin and melanocortin (particularly melanocortin 4 receptor or melanocortin 3 receptor) signaling systems are employed as part of an overall treatment regimen for such animals. Methods for reducing bone fracturability, preserving bone mineral density, maintaining tensile bone strength, and promoting and preserving bone health in patients having renal osteodystrophy, including chronic renal disease (CKD) and end-stage renal disease (ESRD), are also provided. A screening method for selecting candidate compounds that inhibit melanocortin receptor activity is also provided, wherein selected candidate compounds may be used in the formulation of a pharmaceutical preparation for the treatment of uremic patients having or at risk of developing compromised bone health, such as osteodystrophy. |
| priorityDate | 2007-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 198.